ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework
Pharmaceutics · 13.07.2026 · 18 (7) · 852
DOI: 10.3390/pharmaceutics18070852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 13.07.2026. Verfasst von Sanggil Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Team of Biologics Optimization, Division of Biologics Discovery, New Drug Development Center, Osong Medical Innovation Foundation (KBIOHealth), Cheon…. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have received renewed attention in oncology following the clinical and commercial success of agents such as trastuzumab deruxtecan (Enhertu®), which underscored the clinical importance of coordinated optimization of the antibody, linker, payload, and conjugation strategy. Among these parameters, conjugation strategy strongly influences drug-to-antibody ratio (DAR) distribution, pharmacokinetics, manufacturability, and safety. Over the past two decades, ADC conjugation technologies have evolved from first-generation stochastic modification approaches to second-generation site-specific engineering strategies and, more recently, to third-generation site-selective platforms applicable to native antibodies. First-generation approaches remain the most clinically validated and have the strongest regulatory precedent despite their intrinsic heterogeneity. Second-generation approaches improve positional control and DAR homogeneity, but often increase demands on antibody engineering, expression, and process complexity. Third-generation approaches aim to preserve controlled conjugation while reducing sequence-engineering requirements, yet remain limited by a restricted number of accessible sites and less extensive clinical and regulatory experience. In this review, we summarize the evolution of ADC conjugation technologies, highlight representative clinical and translational examples, and discuss the major trade-offs of each platform. We also propose a practical selection framework based on payload properties, required DAR control, antibody stability, manufacturability, and regulatory considerations, with relevance to next-generation ADCs including dual-payload and bispecific formats. Overall, conjugation strategy should be selected according to the scientific, manufacturing, and regulatory requirements of each ADC program rather than on the basis of a presumed technological hierarchy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Team of Biologics Optimization, Division of Biologics Discovery, New Drug Development Center, Osong Medical Innovation Foundation (KBIOHealth), Cheongju 28160, Chungbuk, Republic of Korea.
ORCID-Profile: Hojin Yoo, So-Young Choi
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, S., Lee, S. R., Sohn, M. H., Lee, K., Kim, S. W., Yoo, H., Jeong, H., Oh, D., Chang, J., Yun, J. A., & Choi, S. Y. (2026). ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework. Pharmaceutics, 18(7), 852. https://doi.org/10.3390/pharmaceutics18070852
Vancouver
Kim S, Lee SR, Sohn MH, Lee K, Kim SW, Yoo H, et al. ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework. Pharmaceutics. 2026;18(7):852. doi:10.3390/pharmaceutics18070852
BibTeX
@article{Kim2026,
author = {Kim, Sanggil and Lee, Se-Ra and Sohn, Myung-Ho and Lee, Kyungeun and Kim, Shin-Woong and Yoo, Hojin and Jeong, Hyeonju and Oh, Donghyun and Chang, Jinwoong and Yun, Jeong-Ah and Choi, So-Young},
title = {ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {852},
doi = {10.3390/pharmaceutics18070852}
}
EUVIMED